These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 11202454)

  • 1. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Hoegerle S; Altehoefer C; Ghanem N; Brink I; Moser E; Nitzsche E
    Eur J Nucl Med; 2001 Jan; 28(1):64-71. PubMed ID: 11202454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
    Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
    Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
    Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
    Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E
    Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
    Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
    Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
    Mucha SA; Kunert-Radek J; Pomorski L
    Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.
    Treglia G; Castaldi P; Villani MF; Perotti G; de Waure C; Filice A; Ambrosini V; Cremonini N; Santimaria M; Versari A; Fanti S; Giordano A; Rufini V
    Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):569-80. PubMed ID: 22223169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
    Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
    Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature.
    Gotthardt M; Battmann A; Höffken H; Schurrat T; Pollum H; Beuter D; Gratz S; Béhé M; Bauhofer A; Klose KJ; Behr TM
    Nucl Med Commun; 2004 May; 25(5):439-43. PubMed ID: 15100501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma.
    Gotthardt M; Béhé MP; Beuter D; Battmann A; Bauhofer A; Schurrat T; Schipper M; Pollum H; Oyen WJ; Behr TM
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1273-9. PubMed ID: 16832634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of PET/CT with
    Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
    Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
    Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 16. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Beheshti M; Pöcher S; Vali R; Waldenberger P; Broinger G; Nader M; Kohlfürst S; Pirich C; Dralle H; Langsteger W
    Eur Radiol; 2009 Jun; 19(6):1425-34. PubMed ID: 19156423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
    Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
    J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
    Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
    Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
    Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.